Theranostics drives personalization of neuroendocrine cancer treatment

Canadian researchers share findings at SNMMI

Using PET tool to find coronary lesions at risk of rupture

Could 'drive a paradigm shift' in the early diagnosis of deadly coronary artery disease

Orphan drug improves quality of life for patients with malignant NET gut tumors

Promising Lutathera research highlighted at SNMMI meeting

Over 5,000 expected to attend SNMMI annual meeting in Denver

The year's biggest event for nuclear medicine and molecular imaging

GE touts earlier and faster diagnosis of tumors with lower dose at SNMMI

Checking in with advancements in PET and SPECT

Theranostics takes center stage at SNMMI annual meeting

Renewed optimism over molecular imaging's potential at plenary session

Q&A with Dr. Bennett Greenspan, SNMMI President 2017-2018

Find out what to expect at this year's premier nuclear medicine and molecular imaging event